Related references
Note: Only part of the references are listed.Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study
Stefano Luminari et al.
BLOOD (2019)
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
David M. Kurtz et al.
CELL (2019)
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials
M. J. Maurer et al.
ANNALS OF ONCOLOGY (2018)
Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI
Julio Delgado et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients
M. Gentile et al.
LEUKEMIA (2016)
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
Michael Hallek
LANCET ONCOLOGY (2016)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Share Paper
